Thus, our results suggest that combined blockade of prostate AR and anti-CCL2/CCR2 signalling reduced primary tumour growth and distant metastases (Fig 6G, siAR veh vs. siAR CCR2atg, p = 0.003). Here, CCR2 is linked to neoplasm.